CAS 93438-65-4|Conantokin G
| Common Name | Conantokin G | ||
|---|---|---|---|
| CAS Number | 93438-65-4 | Molecular Weight | 2264.19000 |
| Density | / | Boiling Point | / |
| Molecular Formula | C88H138N26O44 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | / |
Names
| Name | conantokin g |
|---|---|
| Synonym | More Synonyms |
Conantokin G BiologicalActivity
| Description | Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC50 of 480 nM. Conantokin G has neuroprotective properties[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>iGluRResearch Areas >>Neurological DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>iGluR |
| References | [1]. S D Donevan, et al. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol. 2000 Sep;58(3):614-23. [2]. A J Williams, et al. Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J Pharmacol Exp Ther. 2000 Jul;294(1):378-86. |
Chemical & Physical Properties
| Molecular Formula | C88H138N26O44 |
|---|---|
| Molecular Weight | 2264.19000 |
| Exact Mass | 2262.94000 |
| PSA | 1225.52000 |
| InChIKey | HTBKFGWATIYCSF-UHFFFAOYSA-N |
| SMILES | CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(CC(C(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(C(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C(=O)O)C(=O)O)NC(=O)C(CC(C(=O)O)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C(=O)O)C(=O)O)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(N)=O |
| Storage condition | -20°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
Articles27
More Articles| NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr. Drug Targets. CNS Neurol. Disord. 4(2) , 143-51, (2005) Glutamate is the main excitatory neurotransmitter in the central nervous system and it plays a significant role not only in synaptic transmission but also in acute and chronic neuropathologies includi... | |
| The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res. 59(1) , 13-24, (2004) The N-methyl-D-aspartate (NMDA) receptor-gated ion channel is comprised of at least one NR1 subunit and any of four NR2 subunits (NR2A-D). The NR2 subunit confers different pharmacological and kinetic... | |
| The selectivity of conantokin-G for ion channel inhibition of NR2B subunit-containing NMDA receptors is regulated by amino acid residues in the S2 region of NR2B. Neuropharmacology 57(2) , 127-36, (2009) The conantokins are short, naturally occurring peptides that inhibit ion flow through N-methyl-d-aspartate receptor (NMDAR) channels. One member of this peptide family, conantokin-G (con-G), shows hig... |
Synonyms
| 'SLEEPER PEPTIDE' |
| H-GLY-GLU-GLA-GLA-LEU-GLN-GLA-ASN-GLN-GLA-LEU-ILE-ARG-GLA-LYS-SER-ASN-NH2 |
| conotoxin GV |
| M.W. 2264.1 C88H138N26O44 |
| GLY-GLU-GLA-GLA-LEU-GLN-GLA-ASN-GLN-GLA-LEU-ILE-ARG-GLA-LYS-SER-ASN-NH2 |
| Conotoxin GV,Sleeper Peptide |
